ProCE Banner Activity

Immunotherapy for an Elderly Patient With Symptomatic, Rapidly Progressive MSI-High CRC: A Case Study

Clinical Thought
How can immune checkpoint inhibitors improve outcomes in patients with high-risk, progressive colorectal cancer? Read my thoughts on how I incorporate these agents into my practice.

Released: May 10, 2017

Expiration: May 09, 2018

No longer available for credit.

Share

Faculty

E. Scott Kopetz

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Scott Kopetz, MD, PhD, FACP, has disclosed that he holds intellectual property rights with Amgen, Array, Bayer, Genentech, and Taiho and ownership interests with MolecularMatch.